Emerging Evidence for Neoadjuvant Immunotherapy in Esophageal Cancer

Esophageal cancer remains one of the deadliest gastrointestinal malignancies in Australia, with roughly 1,500 new cases recorded annually and five-year survival still below 20 percent. For decades, locally advanced disease has been managed with chemotherapy, radiotherapy, and surgery, yet distant relapse rates stayed stubbornly high. Researchers at the ISDE congress debated whether adding immune checkpoint blockade before resection could shift those numbers.

The conversation has changed since randomised data matured. Combinations of PD-1 inhibitors with platinum-based chemotherapy are producing meaningful gains in pathological complete response, and several regimens have secured regulatory approval overseas. Australian specialists have responded with their own trials, recognising that the local population mixes adenocarcinoma with squamous cell carcinoma requiring different strategies.

The Rationale for Immune Priming Before Surgery

Administering immunotherapy before an operation lets clinicians attack tumour antigens while disease is still in place, training T-cells against a fully vascularised mass. By contrast, adjuvant delivery happens after resection, when micrometastases may already have escaped immune surveillance. Neoadjuvant exposure also reduces the immunosuppressive burden that surgery and anaesthesia place on the host.

Pathological complete response serves as an early surrogate, since patients who achieve pCR tend to enjoy longer disease-free survival. Adding checkpoint blockade appears to lift that figure further, helping surgeons plan lymphadenectomy and anastomotic reconstruction. The trade-off is a small but real risk of immune-related adverse events before theatre.

Pivotal Trial Readouts Reshaping Practice

CheckMate 648 randomised nearly 970 patients to nivolumab plus chemotherapy, nivolumab plus ipilimumab, or chemotherapy alone. The immunotherapy arm produced superior overall survival in those with PD-L1 expression of one percent or higher. KEYNOTE-590, run across 25 countries, showed pembrolizumab with cisplatin and 5-fluorouracil improved survival in both major histologies.

JUPITER-06 added data from China, demonstrating that toripalimab with chemotherapy extended event-free survival in treatment-naive squamous disease. These results build on the older CROSS regimen of carboplatin and paclitaxel with 41.4 Gy of radiation, which had set the previous benchmark. Australian researchers have integrated these combinations into pilot protocols at high-volume centres in Sydney and Melbourne.

Adapting Australian Practice to New Standards

The Therapeutic Goods Administration approved nivolumab for resectable disease in late 2024, with pembrolizumab following for first-line metastatic use. Reimbursement runs through the Pharmaceutical Benefits Scheme, with submissions reviewed by the Medical Services Advisory Committee when indications cross into curative settings. State formularies in New South Wales and Victoria have updated protocols, letting patients start checkpoint blockade while awaiting surgical booking.

Cancer Council Australia is reviewing the evidence base, with consultation closing in 2026. The Australasian Gastro-Intestinal Trials Group has launched recruitment for a perioperative study comparing chemotherapy alone with chemotherapy plus nivolumab, registered through the Australian New Zealand Clinical Trials Registry. Indigenous patients, who face worse outcomes across northern Australia, are being invited through partnerships with Aboriginal Community Controlled Health Organisations.

Biomarker-Driven Patient Selection

Refining patient selection sits at the heart of avoiding overtreatment, and Australian pathology laboratories are scaling immunohistochemistry capacity quickly.

• PD-L1 combined positive score, reported alongside tumour histology at multidisciplinary meetings
• Mismatch repair and microsatellite instability status, run on biopsy material before neoadjuvant planning
• Tumour mutational burden, particularly in younger patients where germline testing may be indicated
• HER2 expression, retained from existing workups to inform trastuzumab eligibility at recurrence

Pathologists at Peter MacCallum Cancer Centre and Royal Prince Alfred have harmonised reporting templates, helping oncologists compare patients across institutions. Turnaround times have fallen from several weeks to about five working days in metropolitan labs.

Multidisciplinary Coordination Across Australian Centres

Coordination between medical oncology, radiation oncology, and upper gastrointestinal surgery has become a daily exercise, with specialist nurses guiding patients through blood tests, imaging, and dental review before therapy.

• Peter MacCallum Cancer Centre, Melbourne, runs a weekly combined clinic for oesophageal cases
• Chris O'Brien Lifehouse, Sydney, has opened a perioperative immunotherapy trial for adenocarcinoma
• Royal Brisbane and Women's Hospital coordinates regional referrals from central and northern Queensland
• Flinders Medical Centre, Adelaide, contributes data to a national biobank for biomarker discovery

These hubs exchange protocols through the Upper Gastrointestinal Cancer Registry, helping smaller hospitals in Hobart, Darwin, and Cairns align supportive care. Telehealth multidisciplinary meetings have proven valuable for regional patients, allowing rural general practitioners to present cases without long-distance travel.

Surgical Timing and Operative Considerations

Most protocols schedule resection four to eight weeks after the final immunotherapy dose, balancing pneumonitis risk against immune escape. Surgeons at the Austin Hospital have published their experience with minimally invasive Ivor Lewis oesophagectomy after immune priming, noting no rise in anastomotic leak rates. Anaesthetic teams now routinely screen for thyroid dysfunction and hypophysitis before induction, since untreated endocrinopathy complicates perioperative fluid management.

Survivorship clinics at Liverpool Hospital and the Princess Alexandra track patients with structured imaging at three-month intervals during the first two years. These protocols help clinicians catch delayed toxicities such as colitis or hepatitis, which can emerge months after the final infusion. Reviewing imaging at multidisciplinary tumour boards keeps the team aligned on surveillance.

For clinicians wanting to act on the evidence now, the most concrete step is to refer eligible patients to an ANZCTR-listed perioperative immunotherapy trial before committing them to standard chemoradiation. Trial coordinators at most metropolitan centres can confirm eligibility within a working week, and early referral preserves the option of enrolment even when public hospital waiting lists for oesophagectomy extend beyond eight weeks.